C4 Therapeutics expands target-first DEL capabilities for molecular glue discovery
Company / institutional announcement · C4 Therapeutics
Source published: · Event / reporting date: 2026-10-29
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
C4 Therapeutics described a DNA-encoded library that incorporates its cereblon-binding ligand collection for target-first molecular glue discovery. The company reported known and novel VAV1 degrader hits as platform validation, while stating that it would not advance VAV1 without a partner. This is a discovery-platform update, not the clinical entry of a new drug candidate.
Why it may matter
Research perspective: Target-first molecular glue screening may create new discovery-partnership opportunities. Hits still require validation of selectivity, degradation mechanism, developability, and translational relevance.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections